<?xml version='1.0' encoding='utf-8'?>
<document id="22577900"><sentence text="Pharmacokinetic evaluation of  rivaroxaban  for the treatment of acute coronary syndromes."><entity charOffset="31-42" id="DDI-PubMed.22577900.s1.e0" text="rivaroxaban" /></sentence><sentence text="Arterial and venous thrombotic states, including myocardial infarction (MI), stroke and deep vein thrombosis with subsequent pulmonary embolism, are a significant cause of cardiovascular mortality and morbidity" /><sentence text=" Factor Xa (FXa) plays a pivotal role in thrombus formation" /><sentence text=" Its inhibition following acute coronary syndromes (ACS) blocks amplification of thrombin generation and subsequent clot formation, resulting in a risk reduction in recurrent MI, stroke and death" /><sentence text=" For this reason, a predictable form of oral anticoagulation continues to be an ongoing need" /><sentence text=" Rivaroxaban , the first oral FXa inhibitor, acts by direct inhibition of FXa and does not require an antithrombin cofactor for its activity"><entity charOffset="1-12" id="DDI-PubMed.22577900.s6.e0" text="Rivaroxaban" /></sentence><sentence text="" /><sentence text="This paper describes the pharmacokinetics (PK) of low-dose rivaroxaban tested in patients with ACS"><entity charOffset="59-70" id="DDI-PubMed.22577900.s8.e0" text="rivaroxaban" /></sentence><sentence text=" Age, gender, renal function and body weight have no clinically significant effects on the PK of the drug in treatment of ACS" /><sentence text=" Caution should be maintained during co-administration of strong CYP3A4 inducers and inhibitors" /><sentence text=" Among patients with moderate and severe hepatic impairment and in those with associated coagulopathies, rivaroxaban however is contraindicated"><entity charOffset="105-116" id="DDI-PubMed.22577900.s11.e0" text="rivaroxaban" /></sentence><sentence text="" /><sentence text="The mortality benefit with low-dose rivaroxaban in ACS patients was first demonstrated in ATLAS ACS2 TIMI-51 trial"><entity charOffset="36-47" id="DDI-PubMed.22577900.s13.e0" text="rivaroxaban" /></sentence><sentence text=" With its rapid oral bioavailability, predictable PK, low drug-drug interaction and no need for monitoring, the use of low-dose rivaroxaban in addition to dual antiplatelet therapy offers an appealing new option in improving outcomes following ACS in the modern era of novel oral FXa inhibitors"><entity charOffset="128-139" id="DDI-PubMed.22577900.s14.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>